Jade Biosciences, Inc. Operating Cash Flow
Jade Biosciences, Inc. (JBIO) reported Operating Cash Flow of -$67.74 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-10
- Jade Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$43.66M.
- Jade Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$24.08M.
- Jade Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$33.65M.
- Jade Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$22.12M.
- Jade Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$94.69M.
- Jade Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$71.20M.
- Jade Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$56.78M.
- Jade Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$39.12M.
| Period end | Net Cash Provided by (Used in) Operating Activities 0 month | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$43.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$67.74M 10-Q · filed 2026-08-10 | -$101.39M derived: sum of 3 quarters · filed 2026-08-10 | -$123.51M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | -$24.08M 10-Q · filed 2026-05-07 | -$57.73M derived: sum of 2 quarters · filed 2026-05-07 | -$79.85M derived: sum of 3 quarters · filed 2026-05-07 | -$100.01M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | -$33.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$55.77M derived: sum of 2 quarters · filed 2026-03-06 | -$75.93M derived: sum of 3 quarters · filed 2026-08-10 | -$94.69M 10-K · filed 2026-03-06 | ||
| 2025-09-30 | -$22.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$42.28M derived: sum of 2 quarters · filed 2026-08-10 | -$61.04M 10-Q · filed 2025-11-14 | -$76.85M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | -$20.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$38.92M 10-Q · filed 2026-08-10 | -$54.73M derived: sum of 3 quarters · filed 2026-08-10 | -$61.53M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | -$18.76M 10-Q · filed 2026-05-07 | -$2.38M 10-Q · filed 2025-04-25 | -$34.57M derived: sum of 2 quarters · filed 2026-05-07 | -$41.37M derived: sum of 3 quarters · filed 2026-05-07 | -$61.80M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$15.81M derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-06 | -$22.61M 10-K · filed 2026-03-06 | -$43.05M derived: sum of 3 quarters · filed 2026-03-06 | -$71.20M 10-K · filed 2025-03-27 | ||
| 2024-09-30 | -$6.80M 10-Q · filed 2025-11-14 | -$27.23M derived: sum of 2 quarters · filed 2025-11-14 | -$60.15M 10-Q · filed 2024-11-12 | -$65.71M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | -$20.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$44.11M 10-Q · filed 2024-08-12 | -$58.91M derived: sum of 3 quarters · filed 2025-04-25 | -$74.52M derived: sum of 4 quarters · filed 2025-04-25 | |
| 2024-03-31 | -$23.67M 10-Q · filed 2025-04-25 | -$38.47M derived: sum of 2 quarters · filed 2025-04-25 | -$54.08M derived: sum of 3 quarters · filed 2025-04-25 | -$69.03M derived: sum of 4 quarters · filed 2025-04-25 | ||
| 2023-12-31 | -$14.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$30.41M derived: sum of 2 quarters · filed 2025-03-27 | -$45.35M derived: sum of 3 quarters · filed 2025-03-27 | -$56.78M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | -$15.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$30.55M derived: sum of 2 quarters · filed 2024-11-12 | -$41.98M 10-Q · filed 2024-11-12 | -$56.84M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | -$14.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$26.37M 10-Q · filed 2024-08-12 | -$41.23M derived: sum of 3 quarters · filed 2024-08-12 | -$50.95M derived: sum of 4 quarters · filed 2024-08-12 | ||
| 2023-03-31 | -$11.42M 10-Q · filed 2024-05-13 | -$26.29M derived: sum of 2 quarters · filed 2024-05-13 | -$36.01M derived: sum of 3 quarters · filed 2024-05-13 | -$44.88M derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2022-12-31 | -$14.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$24.59M derived: sum of 2 quarters · filed 2024-03-25 | -$33.46M derived: sum of 3 quarters · filed 2024-03-25 | -$39.12M 10-K · filed 2024-03-25 | ||
| 2022-09-30 | -$9.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$18.60M derived: sum of 2 quarters · filed 2023-11-13 | -$24.26M 10-Q · filed 2023-11-13 | -$37.35M derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | -$8.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$14.54M 10-Q · filed 2023-08-14 | -$27.63M derived: sum of 3 quarters · filed 2023-08-14 | -$34.16M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$5.66M 10-Q · filed 2023-05-15 | -$18.75M derived: sum of 2 quarters · filed 2023-05-15 | -$25.28M derived: sum of 3 quarters · filed 2023-05-15 | -$29.29M derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | -$13.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$19.62M derived: sum of 2 quarters · filed 2023-03-29 | -$23.62M derived: sum of 3 quarters · filed 2023-03-29 | -$27.40M 10-K · filed 2023-03-29 | ||
| 2021-09-30 | -$6.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$10.53M derived: sum of 2 quarters · filed 2022-11-14 | -$14.31M 10-Q · filed 2022-11-14 | -$17.19M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | -$4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$7.78M 10-Q · filed 2022-08-15 | -$10.66M derived: sum of 3 quarters · filed 2022-08-15 | -$13.10M derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2021-03-31 | -$3.77M 10-Q · filed 2022-05-16 | -$6.66M derived: sum of 2 quarters · filed 2022-05-16 | -$9.09M derived: sum of 3 quarters · filed 2022-05-16 | |||
| 2020-12-31 | -$2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$5.32M derived: sum of 2 quarters · filed 2022-03-30 | -$7.86M 10-K · filed 2022-03-30 | |||
| 2020-09-30 | -$2.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$4.97M 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | -$2.54M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |